All articles by Anthony King
-
BusinessRegeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
Research
Protein impurities found in AstraZeneca’s Covid-19 vaccine stir debate
Compounds might cause side effects but are unlikely to be behind extremely rare blood-clotting events
-
News
Hints that century-old TB vaccine offers an immune boost against Covid-19
Small study is part of global effort examining whether the BCG jab could help in the next pandemic
-
Business
Why manufacturing Covid vaccines at scale is hard
Exploring the pinch points vaccine makers face as they ramp up production
-
News
Green light for world’s first Sars-CoV-2 studies that will infect healthy volunteers
UK trials will assess how well Covid-19 treatments work and if vaccines protect against new virus variants
-
Business
Coronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
News
European commission to reconsider how it announces winners of Marie Curie fellowships
Some researchers applying for the EU scheme were left in limbo over whether or not they had won an award
-
Business
Covid vaccination efforts bolstered by trial results from J&J and Novavax
A miserable January ended with positive news on the vaccine front but new variants added complications
-
News
Old drugs prove their worth against Covid-19 as search continues for life-saving therapies
Thousands of patients have now taken part in trials around the world that have helped sift hope from hype
-
Business
Vaccine approvals offer hope as global Covid cases surge
A handful of vaccines are now approved and the first doses are being given to patients, with trials for many more candidates nearing completion
-
Business
Pfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
Research
Moths draped in stealth acoustic cloak evade bat sonar
Two species have wing scales covered in a complex metamaterial
-
Business
Oxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
Business
Moderna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
Business
Early indications suggest Pfizer–BioNTech’s Covid-19 vaccine is effective
Company claims 90% efficacy at preventing disease, but experts call for data rather than press releases
-
News
Millions of microplastic particles released by some baby feeding bottles
Hot water is key variable responsible for release of large numbers of plastic particles
-
News
First Covid-19 challenge study working with live virus planned for the UK
Pending ethics panel approval, healthy volunteers would be infected with Sars-CoV-2 to help understand disease and test vaccines
-
Business
Protein-based Covid-19 vaccines could overshadow rivals
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
